MINNEAPOLIS, July 9 ATS Medical, Inc.(Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgeryproducts and services, today announced it has obtained new in vivo data tosupport the outstanding wear characteristics of the ATS Open Pivot(R)Mechanical Heart Valve.
The first ATS Open Pivot valve was implanted in Lausanne, Switzerland onMay 4, 1992 by Professor H. Sadeghi and Dr. Demetre Nicoloff. The patient was70 years old at the time of his surgery and enjoyed another active 15 yearswith his ATS Open Pivot valve. He recently passed away from non-valve relatedcauses and his physician and family permitted the explantation of his OpenPivot valve for scientific analysis. Scanning electronic microscopy and laserprofilometry were used to quantify the wear on the carbon portion of thevalve. After 15 years of use and an estimated 560 million opening and closingcycles, the Open Pivot valve displayed no detectable wear.
"We appreciate the willingness of Professor Sadeghi and the patient'sfamily to allow ATS the opportunity to examine the first implanted Open Pivotvalve. Their generous contribution has provided valuable data that validatesthe excellent durability of the ATS valve and is a strong testament of itsclinical benefits for potential patients and their physicians," stated MichaelDale, Chairman, President, and CEO of ATS Medical.
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused oncardiac surgery. The Company, global in scope, is headquartered inMinneapolis, Minnesota. More than 150,000 ATS Open Pivot(R) Heart Valves,which utilize a unique pivot design resulting in exceptional performance andlow risk profile, have been implanted in patients worldwide. The ATS 3f(R)brand encompasses multiple tissue heart valve product offerings at varyingsteps from market introductions to clinical trials to development projectsthat incorporate less invasive valve replacement technology. ATS Medical'sfocus on serving the cardiac surgery community is further strengthened byofferings that include ATS Simulus(R) annuloplasty products for heart valverepair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical website is http://www.atsmedical.com.
This Press Release contains forward-looking statements that may includestatements regarding intent, belief or current expectations of the Company andits management. Actual results could differ materially from those projected inthe forward-looking statements as a result of a number of important factors,including the results of clinical trials, the timing of regulatory approvals,the integration of 3f Therapeutics and the surgical cryoablation business ofCryoCath Technologies, Inc., regulatory actions, competition, pricingpressures, supplier actions and management of growth. For a discussion ofthese and other risks and uncertainties that could affect the Company'sactivities and results, please refer to the Company's filings with theSecurities and Exchange Commission, including its Form 10-K for the year endedDecember 31, 2007 and its most recent quarterly report on Form 10-Q.
SOURCE ATS Medical, Inc.